Special Issue "Chronic Lymphocytic Leukemia: Therapy and Outcome"
Deadline for manuscript submissions: 1 October 2022 | Viewed by 5987
Interests: chronic lymphocytic leukemia; hairy cell leukemia; Hodgkin lymphoma; B cell receptor; targeted therapy; BCL2 inhibitor; BTK inhibitor; prognostic factor
Special Issues, Collections and Topics in MDPI journals
In the last 15 years, our understanding of chronic lymphocytic leukemia has been revolutionized thanks to significant insights into the molecular biology of the disease and the interplay between neoplastic cells and the surrounding microenvironment. The identification of molecules which are pivotal to the survival of malignant cells has allowed us to develop targeted therapies (monoclonal antibodies, kinase inhibitors and BH3-mimetics) that have become the cornerstone of chronic lymphocytic leukemia treatment. Despite these advances, the disease remains incurable and hypogammaglobulinemia, infections, and second primary malignancies still impinge upon patients’ quality of life.
For this Special Issue, we are pleased to invite you to submit original research articles and reviews on any aspect of chronic lymphocytic leukemia are welcome. Research areas may include (but are not limited to) diagnostic pitfall, prognostic factor, predictive factors, critical signaling pathways, comorbidities, targeted therapies, management of kinase inhibitors, Richter syndrome, supporting therapies, and quality of life.
We look forward to receiving your contributions.
Dr. Andrea Visentin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- chronic lymphocytic leukemia
- BTK inhibitors
- BCL2 inhibitors
- PI3K inhibitors
- prognostic factors
- predictive factors
- Richter syndrome